Julian Adong
ID: UNCST-2021-R013487
|
Retention through mHealth for adolescents and young adults with HIV in care
REFNo: HS3722ES
Test the acceptability, feasibility, and preliminary impact of the developed adolescent-tailored mHealth intervention for retention in care of AYWH who are new to or newly re-engaging in care,Iteratively develop a social media-based adolescent-tailored mHealth intervention to improve retention in care for AYWH who are new or newly re-engaging in care,Define the cognitive, environmental, and behavioural challenges and their impact on behavioural intention for AYWH who are new or newly re-engaging in HIV care,To develop and test an mHealth intervention for retention in care for adolescents and young adults with HIV,
|
Mbarara, kamukuzi
Mbarara, kamukuzi
|
Uganda |
2024-02-26 13:34:00 |
2027-02-26 |
105 |
We will enroll male and female adolescents and young adult participants with HIV aged 15-24.
and health care workers aged 18 and above. |
National Institutes of Health/Fogarty International Center |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Bruce Kirenga J
ID: UNCST-2019-R001460
|
SOLIDARITY TRIAL-A phase I/II Randomized Placebo controlled trial to evaluate the Safety and Immunogenicity of Sudan Ebolavirus in Uganda
REFNo: HS3190ES
Phase I (rVSV-SUDV)
1. To determine the safety of rVSV-SUDV candidate SUDV vaccine among adult healthy volunteers in Uganda.
2. To determine the immunogenicity of rVSV-SUDV candidate SUDV vaccine.
Phase II (ChAdox1, CAd3 and rVSV-SUDV)
Primary objectives
1. To determine the safety of ChAdox1, CAd3 and rVSV-SUDV candidate SUDV vaccines among healthy volunteers and persons with stable comorbidities.
2. To determine the immunogenicity of ChAdox1, CAd3 and rVSV-SUDV candidate SUDV vaccines.
Secondary objectives
1. To determine the durability of SUDV-specific induced immune responses following vaccination.
2. To determine the factors associated with optimal vaccine-induced immune responses.
3. To determine the putative cross reactivity by the SUDV vaccine candidates against other ebolaviruses (e.g. Bundibugyo ebolavirus (BUDV) and EBOV).
Exploratory objectives
1. To determine the effect of SUDV vaccines on host gene expression.
2. To determine the T and B cell specific responses and immune profiling in response to vaccination.
3. To determine the effect of SUDV vaccines on the host metabolome.
4. To determine the effect of SUDV vaccines on host innate immune responses.
|
Kabarole, Fort portal
Kampala, Mulago I
Kayunga, Kayunga
Mbarara, Rubindi
Wakiso, Nkumba
Mubende, Kikanddwa
Masaka, Kabonera
|
Uganda |
2024-02-26 13:31:25 |
2027-02-26 |
2121 participants will be recruited in phase II and phase I will recruit 250 participants |
healthy volunteers both male and females will be recruited in the study regardless of the ethnic group they belong to. The participants will recruit people aged 6-65 in to phase I and phase to |
World Health Organization and Ministry of Health Uganda |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
.jpg)
|
Betty Mwesigwa
ID: UNCST-2020-R014667
|
Sabin 003: A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to
Evaluate Safety, Tolerability, and Immune Responses of an
Investigational Monovalent Chimpanzee Adenoviral-Vectored Sudan
Ebolavirus Vaccine in Healthy Adults
REFNo: HS3628ES
To evaluate the safety and tolerability of cAd3-EBO S vaccine
|
Kampala, Central
Kampala, Central
Kampala, Central
|
Uganda |
2024-02-13 17:35:43 |
2027-02-13 |
125 participants |
18 to 70-year old healthy adults |
Sabin Vaccine Institute |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Juliet Babirye Ndimwibo
ID:
|
TREAT INTERACT: Implementing a user involved education- and health system interactive task-shifting approach for child mental health promotion in Uganda
REFNo: HS3144ES
Based on findings from objectives 1-2, develop implementation advice to guide policymakers in school-based child and adolescent mental health (CAMH) management, integration with the health system, and how to implement and sustain large-scale evidence-informed CAMH interventions to contribute towards achieving universal mental health coverage. ,Develop, implement and evaluate an intersectoral supervision, referral and communication model between the health and education sector.,Implement the adapted module-based TREATment mhGAP school program and investigate effective implementation strategies and client outcomes.,Intervention mapping to adapt the mhGAP-IG to a primary school setting, and implementation mapping to develop implementation strategies with user involvement,The main objective of the TREAT INTERACT study is to adapt, implement and evaluate the impact of an adapted school version of the mhGAP-IG that aims to prevent, identify, refer and treat mental health problems in children and adolescents in Uganda through a user involved task-shifting implementation of the mhGAP-IG among primary school staff. This work is divided into 4 work Packages (WPs); each of the specific objectives below represents a single work package.,
|
Mbale, Primary schools
|
Uganda |
2024-02-02 12:05:35 |
2027-02-02 |
612 teachers |
Teachers and pupils at primary schools |
Norwegian research Council |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Harriet Ajilong
ID: UNCST-2022-R005889
|
Assessing Vitamin D serum levels in HIV-positive adolescents 10-19 years with depression in Northern Uganda
REFNo: HS3454ES
To determine the burden of depression in HIV-positive adolescents at Gulu RRH,To assess for serum Vitamin D levels in HIV Positive adolescents 10-19 years with depressive symptoms in Gulu Regional Referral Hospital Methods,
|
Gulu, Laroo
|
Uganda |
2024-01-24 22:30:43 |
2027-01-24 |
380 participants |
HIV Positive adolescents at Gulu Regional Referral Hospital |
Child Global Research Fellowship |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|
